By Zachary Brennan+, 01-May-2015
Though making the switch from batch to continuous manufacturing may be difficult, costly and time consuming, pharma manufacturers and CMOs should begin to consider the switch as in the long-run it will end up saving companies time, money and space, FDA’s CDER Director Janet Woodcock told congressmen in a hearing Thursday.
Related topics:
http://www.pharma-excipients.ch/2015/04/08/continuous-processing-at-interphex-2015/
http://www.innopharmalabs.com/tech/news/glatt-and-innopharma-labs